18F-FSPG PET images, in comparison with MRI and 18F-FDG PET images of the three patients with lung cancer metastases to the brain. Erik S. Mittra Norman Koglin Camila Mosci Meena Kumar Aileen Hoehne Khun Visith Keu Andrei H. Iagaru Andre Mueller Mathias Berndt Santiago Bullich Matthias Friebe Heribert Schmitt-Willich Volker Gekeler Lüder M. Fels Claudia Bacher-Stier Dae Hyuk Moon Frederick T. Chin Andrew W. Stephens Ludger M. Dinkelborg Sanjiv S. Gambhir 10.1371/journal.pone.0148628.g005 https://plos.figshare.com/articles/figure/18F_FSPG_PET_images_in_comparison_with_MRI_and_18F_FDG_PET_images_of_the_three_patients_with_lung_cancer_metastases_to_the_brain_/2586631 <p>For each subject, the whole-body Maximum Intensity Projection (MIP) image of the 18F-FSPG PET scan is shown on the left. In the right column, the axial images through the level of the brain metastasis include the post-contrast T1 MRI (top), 18F-FSPG PET (middle), and 18F-FDG PET (bottom). Physiologic distribution to normal organs are highlighted on the MIP image for subject A, including the liver (l), pancreas (p), kidneys (k), and bladder (b). For the first two subjects (A, B), the small lesions (below 1.5 cm) are clearly visible on MRI and with 18F-FSPG (SUV-A: 11.0, SUV-B: 4.7). With 18F-FDG, however, there is no discernible activity in these lesions. The larger lesion for subject C, who had previously been treated in this region, is again clearly discernable with MRI although the etiology of the enhancement was unclear whether representing residual/recurrent disease versus post-therapy changes. Both the 18F-FDG (SUV 10.1) and 18F-FSPG PET (SUV 21.8) are positive for this subject, but the accumulation of the latter is stronger, and further enhanced by the lack of uptake in the surrounding normal brain tissue (FDG SUV 4.8, FSPG SUV 0.1).</p> 2016-02-18 15:54:50 measure xC imaging orthotopic brain tumors ratio orthotopic brain tumors safety parameters metastatic brain cancer intracranial malignancies tumor uptake brain metastases future studies subject GS 9L model 300 MBq Fischer rats glutamate analogue tumor visualization brain tumors age 50.4 years Clinical Evaluation animal study CT Positron Emission Tomography animal model.Conclusions 18F scan background signal Pilot Preclinical GS 9L glioblastoma cells intracranial malignancies.Experimental DesignFor brain tumor transporter activity pilot study NCT novel PET